Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 19, 2016. The document serves as a transaction notification regarding a Person Discharging Managerial Responsibilities (PDMR) rather than a periodic financial report.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It contains only specific transaction data related to share ownership:
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Type: Increase in notional interest via dividend re-investment under the 2009 Performance Share Plan.
- Transaction Date: July 14, 2016.
- Share Price: £16.285.
- Total Volume: 7,809.558 shares.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document solely discloses an increase in the notional shareholding of Dr. P J T Vallance, President of Pharmaceuticals R&D.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary, risks, contingencies, or unusual items. It is a regulatory disclosure of a specific executive share transaction.
Investor Verification Points
- Verify the total notional share count for Dr. P J T Vallance following this re-investment.
- Confirm the dividend payment date of July 14, 2016, aligns with the company's declared dividend schedule.
- Check the market price of GSK ordinary shares on July 14, 2016, to validate the £16.285 transaction price.